Ambrotose AO® formulation issued Certificate
of Grant for Patents in India and Australia
COPPELL, Texas--(BUSINESS WIRE)--Oct. 15, 2014--
Mannatech,
Incorporated (NASDAQ: MTEX),
the founder of the M5MSM
(Mission 5 MillionSM) social entrepreneurial movement,
the pioneer of nutritional glycobiology and the leading innovator of
naturally-sourced supplements based on Real
Food Technology® solutions, announces the issuance of two
new patents pertaining to its Ambrotose
AO formulations, increasing the total patents held by the company to
98.
Mannatech received the Certificate of Grant from both the Indian and
Australian Patent Offices for their Ambrotose AO formulation pertaining
to the Methods and Compositions for Modified Release of Nutritional
Supplements. The Indian patent was issued on July 21, 2014 and the
Australian patent was issued on September 18, 2014. Both patents will
remain in effect for 20 years from the date of filing. There are
currently 33 patents issued worldwide to Mannatech for the technology
pertaining to this formula. Overall, 98 patents have been issued
worldwide to Mannatech for the technology pertaining to its Ambrotose®,
Ambrotose AO, GI-ProBalance®, and PhytoMatrix®
product formulations and in the field of biomarker assays.
“The vast majority of antioxidant supplements rely on high-dose
synthetic ingredients,” said Dr. Rob Sinnott, CEO and Chief Science
Officer at Mannatech. “We knew when we launched Ambrotose AO back in
2003 that a better approach would be to formulate a synergistic blend of
fat- and water-soluble food-sourced antioxidant nutrients that resemble
the nutrients found in a diet rich in fresh fruits and vegetables.”
“Proof of the benefit of Ambrotose AO supplementation, as measured by
increased serum oxygen radical antioxidant capacity (ORAC), has been
confirmed in three human clinical trials,”1,2,3 continued Dr.
Sinnott. “The product’s safety has been confirmed during these studies
and by 11 years of data collected by our outstanding Safety Monitoring
Program.”
Individuals interested in Mannatech’s products, or exploring its social
entrepreneurial efforts to help fight global malnutrition, can learn
more at Mannatech.com.
Those interested in obtaining technical information and reading
published product studies may visit MannatechScience.org.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing nutrition where it is needed most
around the world. Mannatech’s proprietary products are available through
independent sales Associates around the globe, including the United
States, Canada, South Africa, Australia, New Zealand, Austria, Denmark,
Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan,
Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech
Republic, the Republic of Korea, Mexico, Namibia and Hong Kong. For more
information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “intend” or other similar words or the negative
of such terminology. Similarly, descriptions of Mannatech’s objectives,
strategies, plans, goals or targets contained herein are also considered
forward-looking statements. Mannatech believes this release should be
read in conjunction with all of its filings with the United States
Securities and Exchange Commission and cautions its readers that these
forward-looking statements are subject to certain events, risks,
uncertainties and other factors. Some of these factors include, among
others, Mannatech’s inability to attract and retain Associates and
Members, increases in competition, litigation, regulatory changes and
its planned growth into new international markets. Although Mannatech
believes that the expectations, statements and assumptions reflected in
these forward-looking statements are reasonable, it cautions readers to
always consider all of the risk factors and any other cautionary
statements carefully in evaluating each forward-looking statement in
this release, as well as those set forth in its latest Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, and other filings filed
with the United States Securities and Exchange Commission, including its
current reports on Form 8-K. All of the forward-looking statements
contained herein speak only as of the date of this release.
Reference List
1. Boyd S, Gary K, Koepke CM, et al. An open-label pilot study of the
antioxidant effect in healthy people of Ambrotose AO. GlycoScience &
Nutrition 2003; 4(6): 1-6.
2. Myers SP, Stevenson L, Cheras PA, et al. A forced titration study of
the antioxidant and immunomodulatory effects of Ambrotose AO supplement. BMC
Comp Alt Med 2010; 10(16): 1-16.
3. Bloomer RJ, Canale RE, Blankenship MM, et al. Effect of Ambrotose AO
on resting and exercise-induced antioxidant capacity and oxidative
stress in healthy adults. Nutr J 2010; 9(49): 1-17.
*This statement has not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure,
or prevent any disease.
Source: Mannatech, Incorporated
Mannatech, Incorporated
Ben Hulet, 972-471-7224
bhulet@mannatech.com